CD274 and neoplasm: Tasuku Honjo and colleagues showed that the engagement of PD-1 and its ligand PD-L1 (programmed death- ligand 1) on tumor cells lead to a potent inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.